The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 in one of the most watched regulatory events in the peptide space. Seven peptides were under review for potential inclusion on the 503A bulks list — the list that determines which substances compounding pharmacies can prepare under individual patient prescriptions.
FemPeptides published pre-meeting coverage analyzing what each outcome would mean for women. Now that the meeting has concluded, here's what actually happened and what changes.
What the PCAC reviewed
The seven peptides under review were selected from a longer list of substances nominated for 503A compounding eligibility. The committee evaluated each compound against criteria including safety, evidence of clinical use, whether there's a commercially available equivalent, and whether the compound can be reliably compounded to appropriate quality standards.
The seven were: BPC-157 (gut healing, tissue repair), TB-500/Thymosin Beta-4 (wound healing, hair growth), KPV (anti-inflammatory), MOTS-C (mitochondrial/metabolic), DSIP (sleep), Semax (cognitive), and Epitalon (telomere/longevity).
Why this matters for women specifically
Several of these peptides have disproportionate relevance to women's health:
BPC-157: The pilot study showing 80-100% symptom resolution in 10 of 12 women with interstitial cystitis makes BPC-157 potentially significant for a condition that primarily affects women and has limited treatment options. IBS — 2x more common in women — is another condition where BPC-157's gut-healing properties are relevant.
MOTS-C: Insulin resistance in PCOS/PMOS, postmenopausal bone density, and age-related metabolic flexibility all represent women's health applications for MOTS-C. Its bone-formation effects are relevant to the 80% of osteoporosis patients who are women.
DSIP: Perimenopause insomnia affects a majority of women during the menopausal transition. DSIP's mechanism — promoting delta-wave deep sleep — targets the specific sleep architecture disruption that hormonal changes cause.
KPV: With 80% of autoimmune patients being female, KPV's NF-κB inhibition is relevant to a predominantly female patient population.
What the outcomes mean for access
Peptides recommended for the bulks list: These can continue to be compounded by 503A pharmacies under individual patient prescriptions. Access through compounding pharmacies remains available. Pricing may remain similar to current levels.
Peptides NOT recommended for the bulks list: Compounding pharmacies can no longer prepare these compounds (pending FDA final rulemaking). Access shifts to 503B outsourcing facilities (if they choose to produce the compound), clinical trials (if any are enrolling), or — if an FDA-approved version exists — conventional prescription through retail pharmacies.
Peptides deferred for further review: Some compounds may be deferred for additional data submission. The peptide remains available through compounding during the deferral period, but future access is uncertain.
The broader pattern
The July 2026 PCAC meeting is part of a larger FDA effort to evaluate which substances should be available through compounding pharmacies. This process has been underway since the DQSA was passed in 2013, and it's accelerating as the peptide therapy market grows.
For women's health, the key concern is that peptides with disproportionate relevance to female conditions (IC, PCOS, autoimmune, perimenopause) may be evaluated primarily on evidence bases that don't include sufficient women-specific data — because women have been underrepresented in peptide research. The PCAC's criteria don't explicitly account for sex-specific evidence gaps, which means peptides that might be clinically valuable for women could be evaluated on data that doesn't reflect their potential in the female population.
FemPeptides will continue to track the regulatory process, report on the FDA's final rulemaking, and update access guides as the landscape changes. The July 2026 meeting was a significant milestone, not an endpoint.
For your protocol
If your current peptide protocol includes compounds affected by the PCAC ruling:
Talk to your provider immediately. Your clinician should be aware of the regulatory changes and prepared to discuss alternatives, timeline, and transition planning.
Don't stockpile without guidance. Hoarding peptides creates storage and stability challenges. Your provider can help determine whether and how much supply to secure during any transition period.
Consider the research supplier pathway carefully. If a peptide is removed from compounding eligibility, research-grade suppliers remain an option — but one with different quality assurance standards and legal implications. Understand the distinction before making that shift.
Submit public comment. The FDA accepts public comment during the rulemaking period. Patient testimony about the clinical value of specific peptides — especially for conditions underserved by existing treatments — can influence the final rule. FemPeptides will publish guidance on how to submit effective comments when the comment period opens.
The regulatory landscape is changing. Staying informed is the best way to protect your access to the compounds that matter for your health.